Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 14/20 | 0.53 |
| ▸ | NPC1 | O15118 | 13/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 4/20 | 0.53 |
| ▸ | RELA | Q04206 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919628 | 0.77 | SMN1; SMN2 (0.55) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL22274915 | 0.76 | RAB9A (0.60) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL14470414 | 0.76 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4921114 | 0.75 | MAPT (0.52) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4920495 | 0.73 | MAPT (0.59) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4918661 | 0.72 | KDM4E (0.49) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL12611073 | 0.71 | CYP1A2 (0.63) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL12692443 | 0.71 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL30597799 | 0.70 | HSF1 (0.60) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL26136510 | 0.70 | HSF1 (0.60) | RAB9ANPC1SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | RAB9A 3359/4885NPC1 148/4885SMN1; SMN2 3931/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | RAB9A 3359/4885NPC1 148/4885SMN1; SMN2 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.